Form 4: Enliven Therapeutics CEO Samuel Kintz Sells Shares Under 10b5-1 Trading Plan

Enliven Therapeutics' CEO, Samuel Kintz, executed sales of common stock on June 25, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Samuel Kintz, CEO of Enliven Therapeutics, sold shares of common stock on June 25, 2024.
• The sales were executed under a Rule 10b5-1 trading plan adopted on June 26, 2023.
• A total of 11,422 shares were sold at a weighted average price of $21.6262, and 578 shares were sold at a weighted average price of $22.296.
• Following the transactions, Kintz directly owns 1,076,103 shares through The Kintz & Egan Trust and indirectly owns 88,531 shares through two irrevocable trusts for the benefit of his sons.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the stock sales were conducted under a pre-arranged trading plan, suggesting no specific negative outlook from the CEO.

Positives

• The sales were executed under a pre-arranged 10b5-1 trading plan, which is a legal and transparent way for insiders to sell shares.

Risks

• Insider selling, even under a 10b5-1 plan, can sometimes be perceived negatively by investors.

Industry Context

Insider trading activity is closely monitored in the pharmaceutical industry, as it can provide insights into management's perspective on the company's prospects. Rule 10b5-1 plans are a common tool used to mitigate concerns about insider trading.

Stakeholder Impact

• The stock sale could have a minor negative impact on shareholder sentiment, although the existence of a 10b5-1 plan mitigates this concern.

Key Dates